Assoc Scientist, Drug Product and Technology (DPDT)
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking an Associate Scientist to join our Drug Product Development and Technology (DPDT) team, on the drug product Compatibility/In-Use Stability (CIS) team, supporting all stages of clinical and commercial drug product development. In this role, you will apply biochemical and biophysical methods to evaluate the stability and compatibility of a diverse set of modalities, such as monoclonal antibodies, bispecific antibodies, proteins, antibody-drug conjugates (ADCs), and adeno-associated viruses (AAVs), with drug delivery systems to enable clinical administration and commercialization.
Job description
What you'll do
- Execute IV compatibility/in-use stability studies to support first-in-human (FIH), clinical, and commercial drug product dosing for various therapeutic modalities such as monoclonal antibodies, bispecific antibodies, proteins, ADCs, and AAVs
- Support research and technical development in compatibility/in-use stability
- Perform routine sample analysis to support formulation and product development activities
- Maintain materials, equipment, and laboratory space for the compatibility/in-use stability team
- With guidance, design and execute compatibility/in-use stability studies and other experiments to support testing of therapeutic protein molecules
- Contribute to study protocols and technical documents for internal use and regulatory filings
- Apply statistical knowledge to support study design and data analysis
- Present work at group, departmental, and cross-functional meetings
- Participate in general DPDT lab and instrument maintenance
The environment and physical rhythms of this role
- This is a laboratory environment requiring the ability to multitask and work both independently and collaboratively.
- Detail-oriented, self-motivated teamwork, with strong planning, organizational, and oral and written communication skills, is required.
Must-haves
- B.S. or M.S. in Chemistry, Biochemistry, Biophysics, Pharmaceutical Sciences, or a related field, with 0-5 years of relevant industry experience
- Ability to multitask and work both independently and collaboratively
- Detail-oriented, self-motivated team player with strong planning, organizational, and oral and written communication skills
Preferred / nice-to-haves
- Good understanding of protein chemistry and experience with IV admixture compatibility/in-use stability, protein and formulation characterization, and analytical method development
- Experience with biochemical and biophysical techniques for protein characterization, such as particle size (DLS, HIAC, MFI), chromatography (SEC, IEX, RP), gel electrophoresis (CE-SDS, MCE, icIEF), and spectroscopy (UV-Vis)
- Familiarity with common laboratory software (e.g., Empower, ELN)
Requirements
- B.S. or M.S. in Chemistry, Biochemistry, Biophysics, Pharmaceutical Sciences, or a related field
- 0-5 years of relevant industry experience
- Ability to multitask and work both independently and collaboratively
- Detail-oriented, self-motivated team player
- Strong planning, organizational, and oral and written communication skills
Benefits
- Student Loan Paydown Program
- Tuition Reimbursement
- Family Care Benefits
- Relocation Assistance
- Inclusion, Culture & Well-Being Programs
- Annual Bonuses
- Equity Awards
- Pension or Retirement Benefits
- 401(k) Company Match
- Health and Wellness Programs
- Fitness Centers
- Insurance Benefits
- Paid Time Off
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.